<p>Researcher from Cincinnati Children&#039;s Hospital Medical Center found that type of molecular therapy may be help full for better treatment of non alcoholic fatty liver disorder. The concern research recently appears in Cell Press.</p><p>The researcher reported that increased level of cdk4 (Type of an enzyme) in non alcoholic fatty liver disease patients in mice model can be best inhibited by two drugs that reduces development of hepatic steatosis.<br /><br /><a href="http://www.srlchem.com/" target="_blank" rel="noopener noreferrer"><img src="http://www.microbiozindia.com/images/ASX.png" alt="" /></a></p><h2>According to Researcher,</h2><p>&amp;quot;This is the first study to show that cdk4 triggers development of NAFLD and that inhibiting this enzyme can both prevent and reverse the first step of the disease,&amp;quot; said Nikolai Timchenko, PhD, senior author and head of the Liver Tumor Biology Program at Cincinnati Children&#039;s. &amp;quot;Both of the cdk4 inhibitors we tested are approved by the FDA and in clinical trials for liver cancer, so it should be possible to initiate clinical trials for NAFLD with these drugs soon.&amp;quot;</p><p>NAFLD is type of stage when there is development of abnormal fat in liver even in non alcoholic patients and according to survey 25 percent of the U.S. population -- usually develops in people who are overweight, obese or have diabetes and high cholesterol.</p><p><strong>Story source: </strong>Cincinnati Children&#039;s Hospital Medical Center</p><p>Journal References:</p><p>Nikolai Timchenko, PhD et al. Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease. Cell Reports, June 2016 DOI: 10.1016/j.celrep.2016.06.019</p>